linkedin
BROUGHT TO YOU BY
Exclusive Access, Inclusive Growth

WELCOME TO ET PRIME

BROUGTH TO YOU BY
Exclusive Access, Inclusive Growth
ET Prime
Strategy

Ajay Piramal eyes next leg of growth, but the model of growing through buyouts has stiff competition

His broad plays — a global business of contract manufacturing; making critical-care medicines used in hospitals; and selling OTC drugs in India— all have the potential for significant scale, but they come with their share of challenges. Also, a re-entry in the domestic pharma formulations business won’t be as easy as popping a pill.
font size
FONT SIZE
save
SAVE
saved
SAVED
Gift this article
GIFT ARTICLE
vikasdandekar1
3 Jul 2020 11 Mins Read 5 comments
Piramal Healthcare UK Ltd at Morpeth; image credit: Piramal Group
Piramal Healthcare UK Ltd at Morpeth; image credit: Piramal Group
Like an astute investor, he knows just when to enter the market and exit it. Back in 2010, Ajay Piramal made a pile with an exit that made the Indian pharma market release a collective gasp. Not that he ever left his happy hunting ground of pharma, but he is now dropping hints that he is looking to grab some
readying for the next build-and-exit opportunity like he did in 2010? He says the situation is very different now. Then, pharma was heading into challenging times. Now, immense opportunities await. Either way, he is in no mood for a pause. ( With inputs from Debleena Majumdar; data support by Rochelle Britto) ( Graphics by Mohammad Arshad)
Like an astute investor, he knows just when to enter the market and exit it. Back in 2010, Ajay Piramal made a pile with an exit that made the Indian pharma market release a collective gasp. Not that he ever left his happy hunting ground of pharma, but he is now dropping hints that he is looking to grab some readying for the next build-and-exit opportunity like he did in 2010? He says the situation is very different now. Then, pharma was heading into challenging times. Now, immense opportunities await. Either way, he is in no mood for a pause. ( With inputs from Debleena Majumdar; data support by Rochelle Britto) ( Graphics by Mohammad Arshad)

The latest from ET Prime is now on Telegram. To subscribe to our Telegram newsletter click here.

Gift this story

YOU CAN GIFT 0 MORE STORIES THIS MONTH

Maximum 10 Email IDs allowed

300 characters remaining

Gift Sent Successfully

Limit Reached
Limit Reached

You’ve gifted all the 0 articles from your monthly gift bucket!

Please come back next month.

0 more articles will be waiting for you in your gift bucket.

CONTRIBUTORS WHO HAVE COMMENTED ON THIS STORY

test

user Vikas Dandekar ET Prime, Editor - Pharma and Life Sciences

Current Edition

[[^message]]

Result

[[/message]] [[#message]]

[[message]]

[[/message]]